This company listing is no longer active
Calliditas Therapeutics Dirección
Dirección controles de criterios 1/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Renee Aguiar-Lucander
Chief Executive Officer (CEO)
SEK 18.4m
Compensación total
| Porcentaje del salario del CEO | 36.6% |
| Permanencia del CEO | 7.4yrs |
| Participación del CEO | n/a |
| Permanencia media de la dirección | 3.6yrs |
| Promedio de permanencia en la Junta Directiva | less than a year |
Actualizaciones recientes de la dirección
Recent updates
Analysts Have Lowered Expectations For Calliditas Therapeutics AB (publ) (STO:CALTX) After Its Latest Results
Feb 24
Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?
Jan 12Market Might Still Lack Some Conviction On Calliditas Therapeutics AB (publ) (STO:CALTX) Even After 42% Share Price Boost
Dec 22Is Calliditas Therapeutics (STO:CALTX) Weighed On By Its Debt Load?
Sep 22What You Need To Know About The Calliditas Therapeutics AB (publ) (STO:CALTX) Analyst Downgrade Today
Aug 19Investors Don't See Light At End Of Calliditas Therapeutics AB (publ)'s (STO:CALTX) Tunnel And Push Stock Down 26%
May 26Is Calliditas Therapeutics (STO:CALTX) Using Debt Sensibly?
Feb 24Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?
Nov 25Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Just Slashed This Year's Revenue Estimates By 19%
Aug 24Is Calliditas Therapeutics (STO:CALTX) Using Too Much Debt?
Aug 03Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -SEK 480m |
| Mar 31 2024 | n/a | n/a | -SEK 525m |
| Dec 31 2023 | SEK 18m | SEK 7m | -SEK 466m |
| Sep 30 2023 | n/a | n/a | -SEK 451m |
| Jun 30 2023 | n/a | n/a | -SEK 292m |
| Mar 31 2023 | n/a | n/a | -SEK 393m |
| Dec 31 2022 | SEK 13m | SEK 6m | -SEK 412m |
| Sep 30 2022 | n/a | n/a | -SEK 628m |
| Jun 30 2022 | n/a | n/a | -SEK 608m |
| Mar 31 2022 | n/a | n/a | -SEK 576m |
| Dec 31 2021 | SEK 11m | SEK 5m | -SEK 500m |
| Sep 30 2021 | n/a | n/a | -SEK 452m |
| Jun 30 2021 | n/a | n/a | -SEK 600m |
| Mar 31 2021 | n/a | n/a | -SEK 501m |
| Dec 31 2020 | SEK 7m | SEK 3m | -SEK 433m |
| Sep 30 2020 | n/a | n/a | -SEK 286m |
| Jun 30 2020 | n/a | n/a | -SEK 198m |
| Mar 31 2020 | n/a | n/a | -SEK 54m |
| Dec 31 2019 | SEK 4m | SEK 3m | -SEK 33m |
| Sep 30 2019 | n/a | n/a | -SEK 54m |
| Jun 30 2019 | n/a | n/a | -SEK 35m |
| Mar 31 2019 | n/a | n/a | -SEK 136m |
| Dec 31 2018 | SEK 4m | SEK 2m | -SEK 132m |
Compensación vs. Mercado: La compensación total de Renee($USD1.77M) está por encima de la media de empresas de tamaño similar en el mercado Swedish ($USD754.57K).
Compensación vs. Ingresos: La compensación de Renee ha aumentado mientras la empresa no es rentable.
CEO
Renee Aguiar-Lucander (62 yo)
7.4yrs
Permanencia
SEK 18,367,000
Compensación
Ms. Renee Aguiar-Lucander serves as Director at Genkyotex SA since November 2020. Ms. Aguiar-Lucander has been Chief Executive Officer of Calliditas Therapeutics AB (publ) since May 2017. Prior to joining...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chief Executive Officer | 7.4yrs | SEK 18.37m | sin datos | |
| Chief Financial Officer | 7.2yrs | sin datos | 0% SEK 0 | |
| Vice President of Technical Operations | 1.8yrs | sin datos | sin datos | |
| Head of IR & Sustainability | 1.8yrs | sin datos | sin datos | |
| Group General Counsel | 1.8yrs | sin datos | sin datos | |
| Vice President of Human Resources | 4.8yrs | sin datos | sin datos | |
| Head of Clinical Development & VP of Project Management | 7.8yrs | sin datos | sin datos | |
| Chief Medical Officer | 4.3yrs | sin datos | sin datos | |
| Head of US Marketing | 3.6yrs | sin datos | sin datos | |
| Head of US Sales | 3.6yrs | sin datos | sin datos | |
| President of North America | less than a year | sin datos | sin datos | |
| Vice President of Market Access | no data | sin datos | sin datos |
3.6yrs
Permanencia media
49yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CALTX se considera experimentado (3.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Non-Executive Director | less than a year | sin datos | sin datos | |
| Chairman | less than a year | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Non-Executive Director | less than a year | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
0.08yrs
Permanencia media
Junta con experiencia: La junta directiva de CALTX no se considera experimentada (0.1 años de permanencia promedio), lo que sugiere una nueva junta directiva.